Rhein lysinate suppresses the growth of breast cancer cells and potentiates the inhibitory effect of Taxol in athymic mice

被引:60
作者
Lin, Ya-Jun
Zhen, Yong-Su [1 ]
机构
[1] Chinese Acad Med Sci, Inst Med Biotechnol, Beijing 100050, Peoples R China
[2] Peking Union Med Coll, Beijing 100021, Peoples R China
基金
中国国家自然科学基金;
关键词
epidermal growth factor receptor; human breast cancer; MAPK signal pathway; rhein lysinate; xenograft; TYROSINE KINASE INHIBITORS; TRANSIENT ACTIVATION; INDUCED APOPTOSIS; FACTOR RECEPTOR; C-JUN; EGFR; PATHWAY; ERK; PACLITAXEL; EMODIN;
D O I
10.1097/CAD.0b013e3283182913
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Earlier studies have shown that rhein, one of the major bioactive constituents of the rhizome of rhubarb, inhibits the proliferation of various human cancer cells. However, because of its water insolubility, the antitumor efficacy of rhein is limited in vivo. In this study, we studied the antitumor activity of rhein lysinate (the salt of rhein and lysine and easily dissolving in water) and its mechanism. Inhibition of breast cancer cell proliferation was determined by MTT assay and the mechanism of action of rhein lysinate was investigated by western blot analysis. The therapeutic efficacy of rhein lysinate was evaluated by human cancer xenografts in athymic nude mice. Rhein lysinate inhibited the proliferation of breast cancer cells (MCF-7, SK-Br-3, and MDA-MB-231). The IC50 values were 95,80, and 110 mu mol/l, respectively. Rhein lysinate inhibited the phosphorylation of epidermal growth factor receptor, MEK, and ERK with or without EGF stimulation. It also inhibited tumor growth and enhanced the therapeutic effect of Taxol on MCF-7 xenografts in athymic mice. Rhein lysinate inhibited the phosphorylation of epidermal growth factor receptor and MAPK signal pathway. These results suggest that rhein lysinate might be useful as a modulation agent in cancer chemotherapy. Anti-Cancer Drugs 20:65-72 (c) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins.
引用
收藏
页码:65 / 72
页数:8
相关论文
共 36 条
[21]  
O'Donovan N, 2007, ANTICANCER RES, V27, P1285
[22]  
Pangburn Heather A, 2005, J Carcinog, V4, P16, DOI 10.1186/1477-3163-4-16
[23]  
Qiu LH, 2005, INT J ONCOL, V27, P1441
[24]  
Qiu LH, 2006, ONCOL REP, V16, P907
[25]   Tumorigenesis -: RAF/RAS oncogenes and mismatch-repair status [J].
Rajagopalan, H ;
Bardelli, A ;
Lengauer, C ;
Kinzler, KW ;
Vogelstein, B ;
Velculescu, VE .
NATURE, 2002, 418 (6901) :934-934
[26]   Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer [J].
Roberts, P. J. ;
Der, C. J. .
ONCOGENE, 2007, 26 (22) :3291-3310
[27]   Protein tyrosine kinase Syk modulates EGFR signalling in human mammary epithelial cells [J].
Ruschel, A ;
Ullrich, A .
CELLULAR SIGNALLING, 2004, 16 (11) :1249-1261
[28]   (-)-epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells [J].
Shimizu, M ;
Deguchi, A ;
Lim, JTE ;
Moriwaki, H ;
Kopelovich, L ;
Weinstein, IB .
CLINICAL CANCER RESEARCH, 2005, 11 (07) :2735-2746
[29]   Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation:: A novel-mechanism of lymphangiogenesis in lung adenocarcinoma [J].
Su, JL ;
Shih, JY ;
Yen, ML ;
Jeng, YM ;
Chang, CC ;
Hsieh, CY ;
Wei, LH ;
Yang, PC ;
Kno, ML .
CANCER RESEARCH, 2004, 64 (02) :554-564
[30]  
Sundaram MV, 2006, WORMBOOK, V11, P1